What is Heartbeam, Inc.'s market cap?

Heartbeam, Inc. (BEAT) has a market capitalization of $35.5M and trades on NASDAQ.

Who are Heartbeam, Inc.'s competitors?

Heartbeam, Inc.'s key competitors include Boston Scientific, iRhythm Technologies, Inc., Apple Inc., and others. These companies compete in similar markets and product categories.

Who does Heartbeam, Inc. partner with?

Heartbeam, Inc.'s notable partners include Allegheny Health Network, Mount Sinai Hospital, Northwell Health, and others.

Where is Heartbeam, Inc. headquartered?

Heartbeam, Inc. is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2021.

Heartbeam, Inc.

BEAT

HeartBeam is a medical technology company that develops high-resolution ambulatory cardiac monitoring solutions for use outside of clinical settings.

Market cap

$35.52M-17.3%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

EPS-$0.12Beat by $0.02

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$184.3K

EPS estimate-$0.10

Competitors

By market cap

Apple$4.64T+48.1%

Alphabet Inc.$4.35T+102%

Boston Scientific$66.9B-56.5%

Philips$26.5B+20.1%

iRhythm Holdings, Inc. $3.9B-12.8%

HTF

Heartflow, Inc. Common Stock$2.4B—

Heartbeam, Inc.$35.5M-19.2%

Heart Test Laboratories, Inc.$8.8M+115%

By revenue growth

HTF

Heartflow, Inc. Common Stock+40.6%

iRhythm Holdings, Inc. +27.4%

Alphabet Inc.+17.5%

Boston Scientific+17.4%

Apple+12.8%

By net margin

Alphabet Inc.37.92%+7.1pp

Apple27.15%+2.8pp

Boston Scientific17.26%+5.7pp

iRhythm Holdings, Inc. -7.32%+10.2pp

HTF

Heartflow, Inc. Common Stock-58.42%+20.8pp

Profile

HeartBeam is a medical technology company that develops high-resolution ambulatory cardiac monitoring solutions for use outside of clinical settings. Its proprietary platform captures 3D electrical heart activity to synthesize a 12-lead ECG, enabling the detection of arrhythmias and coronary artery disease through a portable, credit-card-sized device.

Competitive position

HeartBeam holds a unique position as the developer of the first FDA-cleared, cable-free ambulatory 12-lead ECG system, targeting a diagnostic gap between consumer wearables and clinical-grade equipment.

GeographiesUnited States, Serbia

Customer segmentsSpecialized Medical Practices, Hospitals, Direct-to-Consumer

Business modelHardware-as-a-Service, Direct-to-Provider, Subscription SaaS

SuppliersElectronic component manufacturers, Cloud infrastructure providers, Third-party medical device manufacturers, Specialized physicists and engineers

CustomersConcierge physicians, Cardiology practices, Health insurance companies, Hospital-at-home programs

CountryUnited States of America

Listed2021

Employees13.0

CEORobert Eno

SectorHealthcare

IndustryMedical - Healthcare Information Services

Websiteheartbeam.com

FilingsSEC EDGAR

Questions, answered.

What is Heartbeam, Inc.'s market cap?: Heartbeam, Inc. (BEAT) has a market capitalization of $35.5M and trades on NASDAQ.
Who are Heartbeam, Inc.'s competitors?: Heartbeam, Inc.'s key competitors include Boston Scientific, iRhythm Technologies, Inc., Apple Inc., and others. These companies compete in similar markets and product categories.
Who does Heartbeam, Inc. partner with?: Heartbeam, Inc.'s notable partners include Allegheny Health Network, Mount Sinai Hospital, Northwell Health, and others.
Where is Heartbeam, Inc. headquartered?: Heartbeam, Inc. is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2021.